ARCHIVES

NCI-Approved Clinical Trials

This article is from The Cancer Letter archive.

Vol. 29 No. 6 | June 30, 2006

Download PDF Visit The Full Archive

Related Articles

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

December 10, 2004

May issue of Business & Regulatory Report, 8 additional pages, included.

May 28, 2004

NIH News: Board of Governors Appointed to Oversee Clinical Center

October 24, 1996

European Treatment Regimen Less Toxic Than American Method

April 26, 2013

In Brief: Stoval to Receive ACCC Award; Groopman, Sigal, Named to Board of Scientific Advisors

March 12, 1999

Groups Point to NCI Restrictions As Source Of Problems, Discuss Prioritizing Trials

July 11, 2003